Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy

Abstract

This phase I/II study provides Class IV evidence that for patients with early MSA, intrathecal MSC administration is safe, may result in a painful implantation response at high doses, and is associated with dose-dependent efficacy signals.